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S_ary The use of chemotherapy as a form of primary treatment for breast cancer is increasing and, as a
result, more resection specimens contain tumours which have been exposed to cytotoxic drugs. We have
studied the effects of chemotherapy on the tumour morphology and various biological features of breast
carcinoma in a group of 35 patients. These were a group who responded to treatment in a clinical study of the
use of primary chemotherapy designed to reduce tumour bulk prior to surgery. Characteristic morphological
changes, temporally related to the administration of cytotoxic agents, are seen. The malignant cells become
enlarged with vacuolated cytoplasm and vesicular nuclei containing prominent nucleoli; occasionally the nuclei
were angular and hyperchromatic. These features are interpreted as degenerative in nature. In 15 cases
sufficient material was present in the pretreatment biopsies to compare the grade of the tumours before and
after chemotherapy: changes were found in six tumours. Cytotoxic drugs do not induce a consistent pattern of
change in the proliferation and apoptotic indices of individual tumours, but there is a tendency to reduce
proliferative activity over all the tumours as a group. It was also found that chemotherapy is capable of
modifying the expression of the oncoproteins c-erbB-2 and p53 in a minority of cases of breast cancer, usually
resulting in an acquisition of immunoreactive oncoprotein. It is important to be aware of these effects when
studying breast carcinomas removed after chemotherapy.
Chemotherapy is increasingly being used in early breast car-
cinoma, both as a post-operative adjuvant therapy (Early
Breast Cancer Trialists' Group, 1992) and as primary treat-
ment to facilitate breast conservation (Bonadonna et al.,
1990). Accordingly, a growing number of surgical resection
specimens of tumours which have been exposed to the effects
of cytotoxic drugs are now being received in histopathology
laboratories. When assessing the presence or absence of
residual tumour, or if attempts at grading a carcinoma are
made after chemotherapy, it is necessary for histopathologists
to be aware of the changes in morphology of the tumour
cells which can occur following such treatment. Previous
studies of the morphological effects of chemotherapy on
breast cancer have drawn attention to the possibility of
confusing residual tumour with reactive histiocytes (Kennedy
et al., 1990). We too have seen similar changes but do not
agree that they should be mistaken for benign cells. In this
paper, in addition to documenting the tumours' appearances,
we report on the effect of prior chemotherapy on the cellular
proliferative activity in the carcinomas assessed using two
methods: mitotic indices and immunohistochemical staining
with the antibody Ki-Sl. The latter recognises a cell cycle-
associated antigen and can be used to identify the pro-
liferating compartment within a tumour (Camplejohn et al.,
1993). As a corollary to this we also measured the apoptotic
index in the tumour cells and performed immunostaining for
bcl-2 protein, which is thought to protect cells from undergo-
ing apoptosis (Wyllie, 1993). It has also been shown that the
expression of certain oncoproteins in vitro is influenced by
treatment with cytotoxic drugs (Whelan et al., 1992; Fritsche
et al., 1993). We are interested in investigating this further
with particular reference to two oncoproteins whose expres-
sion has been extensively studied in breast carcinoma: c-erbB-
2 and p53. The presence of both proteins has been associated
with a worse prognosis (Paik et al., 1990; Barnes et al., 1993),
and hence it is important to know if their expression can be
affected by chemotherapy in vivo. It has been shown that
DNA damage induced by UV irradiation can give rise to
detectable levels of p53 protein (Hall et al., 1993), and we
investigated whether cytotoxic drugs can induce the same
phenomenon.
Our study group consisted of 35 women with locally
advanced, inoperable primary breast carcinoma as defined by
skcin involvement, tumour fixation and/or supraclavicular
node metastases. Following a diagnostic biopsy, the patients
received combination chemotherapy to reduce the tumour
bulk in an attempt to allow radical surgical treatment. We
were able to compare the tumour characteristics in the
pretreatment biopsy and in the tumour excised afterwards.
By the nature of the clinical protocol the only tissue that was
available both before and after chemotherapy came from
patients whose tumours responded well enough for subse-
quent surgery to be feasible.
Materal and
Between October 1988 and November 1991 61 patients pre-
sented to the ICRF Clinical Oncology Unit with inoperable
locally advanced breast cancer. Forty-seven women received
combination chemotherapy using one of the regimens in
Table I, but 14 patients werejudged to be too frail or too old
for chemotherapy. Each of the cytotoxic drug combinations
consisted of an anthracycline, an antimetabolite and an
alkylating agent used in different doses. All patients had a
biopsy before treatment to confirm the clinical diagnosis of
malignancy. Tlhirty-five tumours responded well enough to
the chemotherapy to allow subsequent surgical removal of
the primary tumour. In 20 the diagnostic procedure had been
one- or two-needle core (Bioptycut) biopsies, while in the
remaining 15 patients core biopsy was unsuccessful or
inconclusive and an incisional biopsy was performed. The
definitive surgical procedure was usually modified radical
mastectomy (33 patients), but two women were treated by
lumpectomy, axillary clearance and radiotherapy following
the patients' expressed wishes.
The needle biopsy specimens were fixed immediately in
formol saline before routine processing and embedding in
paraffin wax. The surgial resection specimens were examined
and cut up fresh. Appropriate tissue blocks were then taken
and fixed in either 2.5% phenol formalin or methacarn
before processing as above. In each case 3 pm sections were
cut and stained with haematoxylin and eosin (H&E). For the
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Table I Chemotherapy regimens used for locally advanced breast
cancer
Adriamycin 30mgm-2 i.v. days 1 and 8
5-Fluorouracil 600mgm-2 i.v. days I and 8 q 4/52 x 4
Cyclophosphamide 100mgm-2 p.o. days 1-14
Epirubicin 30-40mgm-2 i.v. days 1 and 8
5-Fluorouracil 600mg m-2 i.v. days 1 and 8 q 4/52 x 4
Cyclophosphamide lOOmgm-2 p.o. days 1-14
Epirubicin 70mgm2 i.v. day 1
5-Fluorouracil 700mgm2 i.v. day 1 q 3/52 x 6
Cyclophosphamide 700mgm-2 i.v. day 1
Table H Antibodies used for immunohistochemical staining
Antibody Main specificity
Ki-SI Proliferating cells
bcl-2 protein Cells protected from apoptosis
21N c-erbB-2 protein
CMI p53 protein (mutant and wild type)
relevant blocks, immunohistochemical staining using the
antibodies listed in Table II was then carried out using a
standard peroxidase-conjugated, streptavidin-biotin tech-
nique. Immunohistochemical staining for the bcl-2 protein
was performed using the microwave technique recently de-
scribed by Cattoretti et al. (1992) with the single modification
that the sections were heated in a microwave oven (700W)
for 10 min before immunostaining. On H&E-stained sections
the morphology of the tumour before and after chemo-
therapy was compared. To measure mitotic and apoptotic
indices a minimum of 2,000 cells were assessed and the
number ofmitoses or apoptoses was counted using hand-held
haematology counter. On the needle core biopsies this could
often be achieved on one section but, where necessary, sec-
tions cut at multiple 30Sum levels were employed. The indices
were then expressed per 1,000 cells. A similar method was
used to measure proliferative activity with the Ki-SI
antibody, which has been shown to identify a cell cycle-
associated nuclear antigen and, if used appropriately, it can
be used as a marker of cell proliferation in formalin-fixed
tissue (McCormick et al., 1993). Only strongly staining nuclei
were counted in a minimum of 2,000 tumour cells, again
giving an index number of stained cells per 1,000. It has
previously been shown that assessment of Ki-SI in this man-
ner correlates with cell proliferation as measured by flow
cytometry (Camplejohn et al., 1993) and is also an indepen-
dent prognostic indicator in breast carcinoma (Sampson et
al., 1992). The immunostaining for c-erbB-2 and p53 was
noted in a semiquantitative fashion as: absent, + (weak
staining in most cells or stronger staining in <25% cells),
+ + (moderate staining in most cells or stronger staining in
25-75% cells) and + + + (strong staining in >75% cells).
The staining for bcl-2 was either absent or present with very
little difference in the degree of staining when it was pre-
sent.
Results
Using the treatment regimens in Table I, 35 of 47 (75%)
patients achieved either a complete regression or partial
tumour regression sufficent to enable radical surgical resec-
tion. The features of these patients, including clinical pro-
gnostic factors, are given in Table III. No difference in
response rates were found between the three cytotoxic drug
combinations used. In 15 of the 35 cases we received
sufficient tumour tissue in the pretreatment biopsy to allow
the type and grade of the carcinoma to be assessed
confidently. As one ofthe components of tumour grade is the
proportion of tubule formation, it is not our policy to assign
grade on the basis of needle core biopsies. A comparison of
Table m Patient characteristics of the study group before
treatment
Total number of cases 35
Age (years) mean (range) 52 (53-73)
Duration of symptoms (months) median (range) 2.8 (0-36)
Tumour size (cm) mean (range) 6.4 (1.5-5)
Skin involvement/peau d'orange 30
Axillary lymph node involvement (clinical) 28
Supraclavicular lymph node involvement (clinical) 4
Table IV A comparison of tumour type and grade before and after
treatment
Histology Prechemotherapy Post-chemotherapy
Ductal carcinoma
Grade I 1 2
Grade I 4 2
Grade III 8 7
Ductal carcinoma ui situ 0 2
Lobular carcinoma 2 2
Twelve cases showed bizarre, pleomorphic cells after chemo-
therapy.
Tabek V Changes in tumour grade following chemotherapy
Pretreatment grade Post-treatment grade Number of cases
I III 1
II I1
III 1
III I1
DCIS only 2
Tabie VI Histological features of the tumours after chemo-
therapy
No residual carcinoma 4
Ductal carcinoma in situ only 3
Minimal invasive carcinoma 2
Infiltrating ductal carcinoma 21
Infiltrating lobular carcinoma 3
Unclassfiable carcinoma 2
Axillary lymph node status
negtive 8
1-3 positive 12
4-10 positive 12
10 or more positive 3
the grades of these 15 tumours before and after chemo-
therapy is given in Table IV. It can be seen that 6 of the 15
tumours changed grade to either a higher or lower grade
(Table V). The histological features found in the surgical
specimens removed at definitive operation are listed in Table
VI. Four patients had a complete pathological response with
no malignancy remaining in the breast on extensive sampling.
A further three patients showed only residual ductal car-
cinoma in situ (DCIS) but no invasive disease. In 12 cases we
noticed a particular morphological change in the appearance
of the tumour cells following chemotherapy: the cells became
markedly enlarged. Their voluminous cytoplasm appeared
finely vacuolated or 'bubbly'. Genelly the nuclei were
enlarged and vesicular with a prominent single eosinophilic
nucleolus (Figure la and b). In a few cases the nuclei were
enlarged but hyperchromatic and dense with an irregular,
angulated outline (Figure 2a and b). These changes were seen
in both the infiltrating and in situ components of the tumour
and in one patient even in malignant cells in the subcapsular
sinus of an axillary lymph node (Figure 2c). Similar
appearances were not found in the normal breast tissue and
so we regard them as characteristic of prior exposure to
cytotoxic drugs. In cases in which marked tumour regressionCHEMOTHERAPY FOR BREAST CARCINOMA 337
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Fugwe 1 a, Pretreatment biopsy showing an infiltrating ductal
carcinoma composed of islands of moderately pleomorphic cells
(x 130). b, The tumour after chemotherapy contai lae lls
with vesicar nucki and p_ominnt nucleoh, one cell filling an
entire acinus. Here the changes are seen in the in situ component
of the residual tumour (x 130).
had occurred, compact, rather hyaline fibrous tissue was seen
in the stroma at the site of the tumour. In addition, we
formed an impression that the cytotoxic drugs had a
preferential effect on the invasive component of the tumours.
In five cases the residual disease consisted of only DCIS or a
predominance of DCIS with minimal invasive disea. Even
within the larger invasive tumours, the in situ elements
remained prominent. However, in each case the preceding
biopsy had shown a predominance of invasive carcinoma
with a much lesser in situ element, suggesting that there had
been selective loss of the invasive component. However, it
proved to be impossible to quantify this observation in any
meaningful way and so we remain cautious about its
sipgificance.
Assessment of cell proliferation was done using mitotic
indices and Ki-SI immunohistochemical staining. We found
a statistically significant correlation between the two methods
in the pretreatment biopsies (r = 0.28; P = 0.01). However, in
the post-treatment tumours this correlation was lost
(r = 0.02; P = 0.426). The effect of chemotherapy on cell
proliferation was variable, with some tumours showing a rise
in proliferation indices, others showing a fall and a few cases
remaining unchanged. Assessment using both mitotic index
and Ki-Sl staining gave broadly similar results over the
entire study group (Table VII and Figures 3 and 4).
As a measure of cell death induced by chemotherapy we
assessed the apoptotic index before and after treatment in
parallel with immunostaining for the bcl-2 protein. The
results are also shown in Table VI and Figure 5. The low
incidence of bcl-2-positive cases precluded meaningful stati-
stical comparison between the mean apoptotic index in the
bcl-2-positive and -negative groups of tumours. However no
b
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Fugwe 2 a, Pretreatment biopsy of another infiltrating ductal
carcinoma similar to that seen in Figure 1 (x 130). b, In this case
after chemotherapy the tumour cells of the infiltrating component
are agai nlarged but have hyperchromatic, angulated nuclei
(x 260). c, Similar enlarged cells were found in the subcapsular
sinus of a draining axillary lymph node after treatment
( x 260).
correlation of bcl-2 staining with the apoptotic index was
found, but an association between the apoptotic index and
the mitotic index was apparent (r = 0.26; P = 0.016) in the
pretreatment tumours which was not observed following
chemotherapy.
Although a similar pattern of changes in cell proliferation
and apoptosis emerged from the group of tumours as a
whole, individual carcinomas did not always show parallel
changes in each of the parameters studied.
Chemotherapy was also found to modify the expression of
oncoproteins in the malignant cells. We carried out staining
for c-erbB-2 and found that in six tumours there was an
acquisition of the protein in previously negative cases (Figure
6a and b) with an increase in protein expression (from + to338 S.A. RASBRIDGE et al.
Tabie VII Effect of chemotherapy on tumour growth character-
itcs
Table VmI Changes in c-erbB-2
chemotherapy
expression following
Increased Reduced Unchanged
Mfitotic index 18 (58%) 9 (29%) 4 (13%)
Ki-SI index 13 (45%) 14 (48%) 2 (7%)
Apoptotic indcx 19 (62%) 11 (36%) 1 (3%)
bcl-2 indcx 1 (4%) 1 (4%) 25 (92%)
Posiie Negative
Prchmoterapy 21 9
Post-chemotherapy 25 5
lncased, n = 2; decreased, n = 1; unchanged, n = 19; gained,
n = 6; lost, n = 2.
Mitotic index dk
after chemott
acreased~
herapy
Tabe IX Changes in p53 expression following chemotherapy
Posiie Negative
Prechemotherapy 14 16
Post-chemotherapy 20 10
Gained, n = 8; lost, n = 2; haned, n = 20.
_1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31
Case number
(rank order by mitotic index only)
Flge 3 Change in mitotic index after chemotherapy.
Ki-Sl index decreased
after chemotherapy
__.a
Ki-Sl index increased
after chemotherapy
3 5 7 9 11 13 15 17 19 21 23 25 27 29
Case number
(rank order by Ki-Sl staining index only)
Fwe 4 Chang in Ki-Sl stainig index after chemotherapy.
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-20 Apoptotic index increased|
]W-220 after chemotherapy
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Caenumber
(rank order apoptotic index only)
Fgue 5 Change in apoptotic index after chemotherapy.
+ + +) in a further two tumours. Conversely, c-erbB-2 was
lost from one tumour and decreased (from + + + to +) in
two cases (Table VIII). A similar overall pattern was seen on
staining for p53 protein with acquisition of p53 staining in
eight tumours (Figure 7a and b) and loss of staining in two
cases (Table IX). There was no correlation between the
tumours which showed changes in c-erbB-2 expression and
those in which p53 staining was alterd. The oncoprotein
staining was only seen in the malignant cells either before or
after chemotherapy and, when present, was found in the vast
majority of the tumour cells.
A subgroup ofpatients had a particularly good response to
tratment, defined as those in that reponded completely
FI;Se 6 a, Prtreatment biopsy in which the tumour cells are
clearly negtive for c-erbB-2 (x 260). b, Following treatment the
tumour cells show strong membranous staining for c-erbB-2 in
most cells (x 260).
(n = 4), those with only residual DCIS (n = 2) and those with
only minimal residual invasive disease <5 mm in maximum
dimension (n = 3). We compared the pretreatment charac-
teristics of these tumours with the others in the study group
who had sizeable residual tumours. There were significntly
higher proliferation indices in the better responders with a
higher mean mitotic index (12 vs 7 per 1,000 cells, P = 0.058)
and median Ki-Sl index (173 vs 93 per 1,000 cells,
P=0.021). No correlation between response and apoptotic
index or pattern of oncoprotein staining was observed.
This paper describes our observations on the effect of
chemotherapy on a variety of pathological features in a
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F-gwe 7 a, Before chemothrapy the cedls m this tumour did not
stain for p53 protein (x 260). b, After treatment there was
uniform strong nuclear staining for p53 in virtually all the malig-
nant cedls (x 260).
group of carcinomas that were clinially good responders to
treatment; whether simila results pertain to non-responders
is unknown and is currently under investigation. It will be of
paricular interest to see if the observed relationship between
proliferation and the degree of tumour response to chemo-
therapy is maintained. This observation is of potential value
in planning treatment protocols. In 23 of 35 cases the
pretreatment biopsy was a needle core specmen, which raises
the problem of tumour sampling for biological studies. In the
larger specimens examined, either before or after chemo-
therapy, the expression of the various parameters measured
was found to be fairly uniform throughout the tumour. It is
felt, therefore, that no signficant bias was introduced by the
use of core biopsies.
Morphological changes after chemotherapy
That chemotherapy can cause alterations in the morphology
of tumour cells was first documented in 1960 by WaIler, who
noted nuclear enlargement and vacuolation with cytoplasmic
swelling and vacuolation after the systemic administration of
busulphan. Similar features were seen in cytological aspirates
(Brifford et al., 1989). A more systematic study of the effects
of combined tamoxifen and cytotoxic drug treatment on
breast carcnoma was caied out by Kennedy et al. (1990).
In 16% of the tumours, cells with a morphology very similar
to that described in our cases was seen but differentiation of
these cells from a benign histiocytic reaction was stressed. We
believe that this is misleing and that the cells observed
have frankly malignant features. In our opinion the main
rationale for recognising this characteristic cellular
appearance is to avoid attributing too high a grade to the
tumour when attempting to provide some prognostic inform-
ation. Indeed the value of either histological or cytological
grading following treatment is doubtful. We interpret the
changes as degenerative with nuclear enlargement and vacuo-
lation followed by hyperchromasa within the enlarged
nuclei. In two patients whose tumours subsequently recurred
loally the histological appearances of the recurrece were
similar to the primary biopsy sample and did not show any
of the altered malignant cells. Thus, the morphological
changes appear to be a transient phenomenon related to the
administration of the cytotoxic drugs. This has been noted in
relation to similar changes in the urothelium (Forni et al.,
1964).
Changes in tnour kinetics after chemotherapy
The main mode of action of cytotoxic drugs is to kill cyclng
cells. Skipper et al. (1964) have shown that a given dose of
chemotherapy will kill a constant fraction of the vulnerable
cell population and that a greater fractional cell kill is
achieved in more rapidly growing tumours. Since the
majority of tumours in this study were of high grade and
hence dividing rapidly, the proportion of proliferating cells
might be expected to be reduced by the cytotoxic agents.
However, this was seen in only a half to a third of cases; in
most of the remfainder there was an increase in the cell
proliferative activity. The latter finding can be explained by
consideration ofkinetic studies of the growth index of maig-
nant tumours, which have shown that initially the tumour
grows in an exponential fashion but, as it gets larger, growth
slows. A mathematical model in which the initial exponential
growth index also declines exponentially - a Gompertzian
function (Laird, 1964) - has been shown to fit the clinically
observed growth indices of tumours and also the growth of
malignant cells in vitro (Akanuma, 1978). One consequence
of this model is that successful treatment of larger tumours
results in a reduction of tumour size with an improvement in
the vascular supply of nutrients to the tumour cells, which
then begin to regrow more rapidly. This model therefore can
provide an explanation of the increased index of cell pro-
liferation that we observed in a significant proportion of
tumours. The timing of the definitive surgery was governed
by clinical considerations and, although each tumour would
have been removed approximately 3 weeks following cessa-
tion of the chemotherapy, we cannot exclude the possibility
that some of the differences in cell proliferative responses
may be due to removal of tumours at different points of
recovery after treatment. Other reports of breast carcinoma
proliferative changes following treatment have shown
broadly similar results with no consistent pattern of response
even in tumours which show remission with chemotherapy
(Kennedy et al., 1989; O'Reilly et al., 1992; Skoog et al.,
1992).
Following chemothapy all previous correlation between
mitotic index and Ki-Sl staining was lost. The function of
the antigen that is recognised by Ki-Sl is unknown, but its
apparent dissciation from mitosis may reflect a different role
in the DNA repair/replication initiated by chemotherapy
from that induced by other proliferative stimuli.
The mechanism by which cell death, and hence loss of
tumour bulk, occurs has been the subject of much recent
study. Many cytotoxic agents appear to activate the intracel-
lular pathways which culminate in apoptosis. This is the final
common pathway for many processes which are lethal to
cells (Searle et al., 1975; Dyson et al., 1986; Eastman, 1990;
Lennon et al., 1990; Kyprianou et al., 1991). However, there
is some experimental evidence that cytotoxic drugs may act
in a different fashion in higher doses when they cause direct
tissue necrosis (Dvyson et al., 1986). In our cases the overall
change in apoptotic indices mirrored the changes in cell
proliferation with an increase in apoptoses inapproximately
one-third of cases but a fall in the numbers of apoptoses in
the majority of tumours. No gross areas of tumour necrosis
were seen histologically. Rather the site of the tumour
clinically was often occupied by hyaline fibrous tissue; this
could conceivably represent the aftermath of previous nec-
rosis. We found bcl-2 staining in 26% (7/27) of pretreatment340 S.A. RASBRIDGE et al.
biopsies and no correlation with the apoptotic index. This is
in contrast to other studies in which 70-90% of invasive
breast carcinomas were found to contain bcl-2 immunoreac-
tivity (Chan et al., 1993a,b; Nathan et al., 1993). The correla-
tion between bcl-2 reactivity and tumour grade is uncertain:
Chan et al. (1993a,b) noted a negative correlation between
bcl-2 and the grade of infiltrating ductal carcinomas with
only 40% of grade 3 carcinomas staining for bcl-2.
However no correlation with tumour grade was found in a
larger study (Nathan et al., 1993). Chan et al. (1993b) also
found a stronger correlation between the apoptotic index and
the expression of bcl-2 in tumours with a low mitotic index
(<6 mitoses per 1,000 cells). We postulate that the lower
index of bcl-2 staining seen in our cases is related to the fact
that they are mainly high-grade tumours with high mitotic
indices (mean eight mitoses per 1,000 cells). Indeed, in a
multiple regression analysis of our group of tumours apop-
tosis was correlated with the mitotic index and not with bcl-2
staining. A similar correlation ofthe apoptotic index with the
mitotic index was noted by Chan et al. (1993a). Thus, these
rapidly proliferating tumours appear to be in a 'high tur-
nover state' in which there is an increased chance of apop-
tosis amongst proliferating cells. It would appear that the
proliferative stimulus, driving the cells into a state in which
they are vulnxrable to apoptosis, overrides the protective
effect of bcl-2 against apoptosis (Dive et al., 1992).
Changes in oncoprotein expression after chemotherapy
The changes that were observed in the expression of the
oncoproteins c-erbB-2 and p53 after chemotherapy are of
interest. Experiments in vitro have shown that treatment of
cells grown in cell culture with vincristine can induce the
expression of c-erbB-2 on previously negative cells (Whelan
et al., 1992). This is the first evidence that, at least in a
proportion of cases, the same effect can be demonstrated in
vivo following treatment with combination chemotherapy.
The c-erbB-2 protein is thought to behave as a constitutively
active growth factor receptor, and expression of the onco-
protein has been shown to correlate with cell proliferation as
measured by the thymidine labelling index (Barnes et al.,
1991). The emergence of cells bearing this oncoprotein after
chemotherapy is consistent with the early recovery of a cell
population that possesses a growth advantage and is in keep-
ing with the Gompertzian model of increased cell prolifera-
tion in smaller tumours.
Currently p53 protein is thought to act as a 'genomic
guardian' which arrests cells with DNA mutations at the
GI-S checkpoint and prevents cell replication with the pro-
pagation of the mutation (Lane, 1992; Vogelstein & Kinzler,
1992). Treatment of cells in vitro with irradiation, ultraviolet
light and radiomimetic drugs has been shown to induce
accumulation of p53 in a response to DNA damage (Wyn-
ford-Thomas, 1992; Fritsche et al., 1993; Hall et al., 1993).
Similar effects have been found in the skin in vivo following
UV exposure (Hall et al., 1993). Initially the detection ofp53
protein by immunohistochemistry was thought to be possible
only when abnormally stabilised mutant protein was present.
More recent reports have emphasised that accumulation of
even wild-type p53 can also allow its immunohistochemical
detection but that the function of the protein may still be
abnormal (Walker et al., 1991). No results have been pub-
lished of the effect ofcytotoxic drugs administered in vivo on
p53 expression. We interpret the acquisition of p53 staining
in 8 of30 cases as being the result of accumulation ofnormal
protein as a result of gentoxic damage caused by the
cytotoxic drugs and not new mutations in the p53 gene.
Thus, this is suggested to be further support for the role of
p53 in DNA repair in a human tumour in vivo.
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